New challenges in the treatment of dyslipidemia and cardiovascular risk;Nuevos retos en el tratamiento de las dislipidemias y del riesgo cardiovascular

Revista Clinica Espanola

Volumn 209, Issue 5, 2009, Pages 241-244

  Lopez Menchaca R ^a   Suarez Fernandez C ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIOXIDANT; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; VASODILATOR AGENT;

BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; FIBRINOLYSIS; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LEUKOCYTE ACTIVATION; LIPID METABOLISM; MONOTHERAPY; NOTE; RISK REDUCTION; THROMBOCYTE AGGREGATION INHIBITION; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; RISK FACTORS;

EID: 67650714212     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/S0014-2565(09)71241-X     Document Type: Article

References (19)

1. CTT Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
2. P. Libby The forgotten majority: unfinished business in cardiovascular risk reduction J Am Coll Cardiol 46 2005 1225 1228 (Pubitemid 41615541)
3. H.B. Brewer High-density lipoprotein: a new potential therapeutic target for the prevention of cardiovascular disease Artherioscler Thromb Vasc Biol 24 2004 387 391
4. N. Sarwar, J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, and S. Bingham Triglycerides and the risk of coronary heart disease. 10,158 incident cases among 262,525 participants in 29 western prospective studies Circulation 115 2007 450 458 (Pubitemid 46184196)
5. J.L. Palma Gámiz, I. Conget Donlo, V. Bertomeu González, J.F. Ascaso Gimilio, J.R. González Juanatey, and E. Alegría Ezquerra Prevalencia del síndrome metabólico en pacientes con enfermedad cardiovascular en España: Estudio CLYDIA Med Clin (Barc) 128 2007 407 413
6. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, and T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 1977 707 714 (Pubitemid 8110784)
7. M. Chapman Beyond LDL cholesterol reduction: the way ahead in managing dyslipidaemia Eur Heart J 7 Suppl 2005 F56 F62
8. P. Barter, A. Gotto, J. LaRosa, J. Maroni, M. Szarek, and S.M. Grundy HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310 (Pubitemid 47481452)
9. D.J. Gordon, J.L. Probstfield, R.J. Garrison, J.D. Neaton, W.P. Castelli, and J.D. Knoke High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies Circulation 78 1989 8 15 (Pubitemid 19043669)
10. S. Nicholls, E.M. Tuzcu, I. Siphi, A.W. Grasso, P. Schoenhagen, and T. Hu Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 2007 499 508 (Pubitemid 46220805)
11. B.G. Brown, S.K. Hinckley, and X.Q. Zhao Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials Curr Op Lipid 17 2006 631 636 (Pubitemid 44729955)
12. P.K. Shah, S. Kaul, J. Nilsson, and B. Cercek Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I Circulation 104 2001 2376 2383 (Pubitemid 33049524)
13. B. Norderstgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen Nonfasting tryglycerides and risk of myocardial infarction, ischemic heart disease and death in men and women JAMA 298 2007 299 308 (Pubitemid 47080484)
14. S.J. Robins, D. Collins, J.T. Wittes, V. Papademetriou, P.C. Deedwania, and E.J. Schaefer Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591 (Pubitemid 32240250)
15. Action to Control Cardiovascular Risk in Diabetes: ACCORD. Clinicaltrials. gov, NCT00000620 (consultado el 21 de septiembre de 2008). Disponible en: http://www.clinicaltrials.gov/ct2/show/NCT00000620
16. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
17. B.G. Brown, X.Q. Zhao, A. Chait, L.D. Fisher, M.C. Cheung, and J.S. Morse Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592 (Pubitemid 33126837)
18. J.F. Paolini, Y.B. Mitchel, R. Reyes, U. Kher, E. Lai, and D.J. Watson Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia Am J Cardiol 101 2008 625 630
19. Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. Clinicaltrials.gov, NCT00461630 (consultado el 21 de septiembre de 2008). Disponible en: http://www.clini-caltrials.gov/ct/show/NCT00461630?order=1